WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 6801 Infant (under 12 months) mortality rate: 712
GDP / capita (US$): 1'9671 Child (under 5 years) mortality rate: 982

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 31'281  30'552  29'825  29'105  28'398  20'595  11'731  13'180 
Births 1'034  1'042  1'053  1'066  1'079  1'048  643  657 
Surviving infants 967  973  981  991  1'001  948  560  543 
Pop. less than 5 years 4'848  4'905  4'964  5'010  5'030  4'263  2'301  2'511 
Pop. less than 15 years 14'325  14'244  14'136  13'990  13'802  10'187  5'708  6'161 
Female 15-49 years 7'070  6'793  6'527  6'280  6'054  4'277  2'509  2'888 

Number of reported case

(Click for retrospective incidence data for Afghanistan)
Diphtheria 84  368  1'939 
Japanese encephalitis
Measles 492  430  2'787  3'013  1'989  6'532  1'609  32'455 
Mumps
Pertussis 371  1'497  896  411  15'748 
Polio* 28  17  46  81  30  120  48  880 
Rubella 43  367  750  46 
Rubella (CRS)
Tetanus (neonatal) 17  13  21  20  23  139  16 
Tetanus (total)** 39  24  37  20  23  131  1'618 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Afghanistan)
Vaccine year result method % card seen                                                
BCG 2012  78  CES   66  97  89  89  83  68  30  30  33 
DTP1 2012  78  CES   66  99*  98  99*  94  86  48 
DTP3 2012  60  CES   66  95  90  87  82  66  24  25 
DTP4         
IPV1         
HepB_BD         
HepB3 2012  60  CES   66  95  90  87  82  66 
Hib3 2012  60  CES   66  95  90  87  82  66 
JapEnc         
MCV1          88  82  81  75  62  27  20  11 
MCV2          60  56  54  48  46 
PCV1          99* 
PCV3          63 
Pol3 2012  64  CES   66  90  90  87  82  66  24  25 
Rota1         
Rota_last         
Rubella1         
TT2plus 2011  35       85  63  76  75  65  20 
PAB         
VAD1          15 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Afghanistan)
BCG 86  78  78  71  68  30  30 
DTP1 82  80  78  78  72  48  50  22 
DTP3 75  70  67  68  66  24  25 
HepB3 75  70  67  68  66 
HepB_BD
Hib3 75  70  67  68  66 
MCV1 66  60  59  64  62  27  20  11 
MCV2 39  35  33  31  29 
PAB 70  65  60  60  79  32  13 
PCV3 40 
Pol3 75  70  67  68  66  24  25 
Rota_last

Number of districts in the country 329  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
99 
   
/
|
|
\
Greater or equal to 90% 58
From 80 to 89% 10
From 50 to 79% 22
Less than 50% 9
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HepB birth; No
IPV 14 weeks Yes From September 2015
Measles 9, 18 months; Yes
OPV birth; 6, 10, 14 weeks; 9 months; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
TT 1st contact; +1, +6 months; +1, +1 year; Yes CBAW

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2015-2019  2011-2015  2011-2015  2011-2015  2010-2015  2006-2010  2006-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 321  321  321  321  324  324 

System performance

Total Nº districts in country number 329  329  329  329  329  329  329 
Nº districts with DTP3 coverage >=80% number 224  219  195  187  190  185  191 
% of districts with DTP3 coverage >=80% From 0 to 100% 68  67  59  57  58  56  58 
Nº districts with measles (MCV1) coverage >=95% number 145  136  111  99  93  68  67 
% of districts with MCV1 coverage >=95% From 0 to 100% 44  41  34  30  28  21  20 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR No  No  No  No    Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%           11 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.